Trial Profile
Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Oct 2023
Price :
$35
*
At a glance
- Drugs Belinostat (Primary)
- Indications Colorectal cancer; Lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 01 May 2022 According to a Form 6-K, 2022, company SEC filing, GlaxoSmithKline has changed its name to GSK.
- 04 Jul 2019 Results evaluating the effect of belinostat exposure on liver function in patients with advanced cancer and varying degrees of liver dysfunction, are published in the British Journal of Clinical Pharmacology
- 26 Oct 2017 Status changed from recruiting to completed.